REPLi: Identify Prot​​​​​​​​​​​​​​ease Substrates

Do you have an unidentified protease? Do you want to know its target sequence?

A Rapid Endopeptidase Profiling Library (REPLi) is a generic Fluorescent Resonance Energy Transfer (FRET) Peptide Library designed specifically to overcome common hurdles and simplify the protease profiling process. Mimotopes’ REPLi Library is available off-the-shelf and ready to use from our online catalogue.

Find out more

REPLi Requirements

An advantage of REPLi is it doesn’t require any prior knowledge of the proteases under investigation to help define the sequence of the protease cleavage site.

This peptide library comprises 3375 peptides divided into 512 distinct pools, each containing only 8 peptides so it can be rapidly deconvoluted to identify the specific sequences cleaved by your proteases.

Proteases are valuable drug targets in disease treatment, therefore fast identification of protease substrates directly from cells and tissues is invaluable.

How FRET Functions

FRET is commonly used to investigate protein interactions, including proteolysis.

In REPLi, the tripeptide core sequence is book-ended by glycine residues, with a fluorescent donor and quenching acceptor on opposite ends. When proteases cleave the peptide sequence, the quenching effect ends and the donor fluoresces.

Through real time proteolytic activity monitoring, this peptide library design provides a quantitative measure of the differences in substrate processing of low-abundant proteins, as disease markers.

Is REPLi Reliable?

Validation studies with well-characterised representative proteases from each of the four mechanistic protease classes have shown the impressively specific and sensitive capabilities of REPLi.

Results obtained from REPLi can be followed up with precise directed analysis using purified custom peptides or peptide libraries.

CONTACT US TODAY

for a peptide quote! 

☎ +61 3 9565 1111

✉ australia@mimotopes.com

☎ +1 651 603 0909

 useast@mimotopes.com

☎ +61 3 9565 1111

✉ asia@mimotopes.com

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

 for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Pharma’s path to Net Zero: Targeting Scope 3 emissionsGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: DycemGo to article: In DepthGo to article: Pharma’s path to Net Zero: Targeting Scope 3 emissions Go to article: Profit vs inquiry: Clash of objectives in academic and commercial trialsGo to article: CTO Europe 2023: A snapshot of challenges and opportunities in oncology Go to article: The future of cell and gene therapy manufacturing Go to article: VPAS is dead, long live VPAGGo to article: Q&A: European Pharmaceutical legislation: hindrance or help?Go to article: NatoliGo to article: NiproGo to article: YearbookGo to article: Yearbook contentsGo to article: UK’s pharma regulatory scene reckons with changes in 2023Go to article: Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023Go to article: Top themes of 2023: AI, precision medicine, virtual care, digital therapeutics Go to article: Humira biosimilars set the stage for long-awaited 2023 US launchesGo to article: Inside the hunt for an Alzheimer’s disease vaccineGo to article: Pathbreakers: The journey of first genericsGo to article: NASH drugs race to cross the finish lineGo to article: Fighting AMR with a value and subscription modelGo to article: Cancer treatment uncertainty: European nations struggle with drug shortages Go to article: Why are haemophilia gene therapies so expensive? Go to article: Top themes for the healthcare sector in 2024 Go to article: ListingsGo to article: EventsGo to article: The top 100 most innovative companies in the US in 2023Go to article: Buyer's GuidesGo to article: Next issue